Health Canada conditionally approved Leqembi (lecanemab) to treat mild cognitive impairment or dementia due to early ...

Health Canada has conditionally approved Leqembi (lecanemab) for certain adults with early Alzheimer’s disease, making it the first treatment approved in Canada that targets an underlying cause of ...

The European Commission has approved Eli Lilly‘s monthly infusion therapy Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease. The treatment targets sticky protein clumps, or ...

The U.S. Food and Drug Administration (FDA) has approved a more gradual titration dosing schedule for Kisunla (donanemab) for people with early symptomatic Alzheimer’s disease based on evidence that ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease. The company ...

Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E ...

Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other disorders, that will be used in future clinical trials. The ...

After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing ...

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease ...